S&P 500 Healthcare Sector SPDR (XLV)

Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Are Wall Street analysts favoring West Pharmaceutical’s stock now as GLP-1 drugs gain prominence?

Despite Align Technology's weak performance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Do Wall Street analysts favor Labcorp’s stock, given its solid performance?

IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish...

STERIS has lagged behind the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.

While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Although ResMed has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Despite Elevance Health's outperformance relative to the broader market over the past 52 weeks, Wall Street analysts remain cautiously optimistic about the stock's prospects.

Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.